Acceleron Pharma

$124.61
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.03 (-0.02%) Today

$0.00 (0.00%) As of 9:00 AM UTC after-hours

Why Robinhood?

You can buy or sell XLRN and other stocks, options, and ETFs commission-free!

About XLRN

Acceleron Pharma Inc. Common Stock, also called Acceleron Pharma, is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis in June 2003 and is headquartered in Cambridge, MA. The listed name for XLRN is Acceleron Pharma Inc. Common Stock.

CEO

Habib J. Dable

Employees

237

Headquarters

Cambridge, Massachusetts

Founded

2003

Market Cap

7.62B

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

454.94K

High Today

$125.82

Low Today

$123.24

Open Price

$125.16

Volume

261.66K

52 Week High

$136.25

52 Week Low

$50.80

Collections

Analyst Ratings

85%

of 13 ratings

Buy

85%

Hold

Sell

XLRN Earnings

-$0.95

-$0.63

-$0.32

$0.00

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

— per share

Actual

Expected Feb 25, After Hours